This is not an ADB material. The views expressed in this document are the views of the author/s and/or their organizations and do not necessarily reflect the views or policies of the Asian Development Bank, or its Board of Governors, or the governments they represent. ADB does not guarantee the accuracy and/or completeness of the material's contents, and accepts no responsibility for any direct or indirect consequence of their use or reliance, whether wholly or partially. Please feel free to contact the authors directly should you have queries.

# PhilHealth Coverage for Diabetes-Related Treatments

April 2, 2025





### **Outline**

- 1. Legal Basis National Health Insurance, UHC
- 2. Background
- 3. Coverage for DM-related treatments
- 4. Utilization for DM-related treatments
- 5. Future Direction





## **Legal Basis**



### National Health Insurance Act (RA No. 7875, as amended by RA Nos. 9241 and 10606)

National Health Insurance Program to provide responsive benefit packages and improve its benefit packages to meet the **needs** of its members.



### **RA No. 11223 (UHC Act)**


PhilHealth to be the national strategic purchaser of individualbased health goods and services, ensuring equitable access to health services without causing financial hardship





### Philippines Universal Health Care Law (RA 11223)

Whole of system, whole of government, and whole of society approach



### PhilHealth mandate:

- Expand and improve benefits coverage
- Design an explicit health benefits package (HBP)
- Develop the benefit plan
   Benefits Development Planning
   Protocol (BDPP)
- Review HBP periodically

All Filipinos are covered by social health insurance





### Criteria for Health Benefit Package Prioritization

According to **need** and not according to want (RA 7875, as amended by RAs 9241 & 10606)

- Epidemiologic Data or Burden of Disease What people are dying of & what people are getting sick of (DALYs)
- 2. Financial Risk Protection with Equity Consideration
- 3. Health Technology Assessment (HTA)
  Recommendation

- 4. Other Considerations
- Sustainable Development Goals
- Philippine Development Plan 2023-2028
- National Objectives for Health 2023-2028
- Legislative Mandates (e.g., Mental Health Act, NICCA, Magna Carta for PWD, Rare Disease Act, etc.)
- Public Interest

Adapted from PhilHealth CO 2024-0003, "Benefits Development Planning Protocol"






### **Burden of Disease**

Philippine Burden of Disease 2021: The Vital Few Thirty-five diseases already account for 80% of the DALYs

Noncommunicable Diseases

Communicable, Maternal, Neonatal, and Nutritional Disorders

Injuries



Source: Wong J. Phil Burden of Disease. January 2025





The top 10 diseases already account for 47% of the DALYs


| Cause of death or injury | Percent DALY | Cumulative Percent |
|--------------------------|--------------|--------------------|
| Ischemic heart disease   | 9.1          | 9.1                |
| Stroke                   | 7.6          | 16.7               |
| Neonatal disorders       | 6.9          | 23.6               |
| Lower respiratory        |              |                    |
| infections               | 5.1          | 28.7               |
| Diabetes mellitus        | 3.7          | 32.4               |
| Chronic kidney disease   | 3.6          | 36.0               |
| Tuberculosis             | 3.5          | 39.5               |
| Interpersonal violence   | 2.8          | 42.3               |
| Congenital birth defects | 2.7          | 45.0               |
| Headache disorders       | 2.4          | 47.4               |

Source: Wong J. Phil Burden of Disease. January 2025





The top five risk factors contributing to disease are: hypertension, malnutrition, air pollution, tobacco, and dietary risk



#### **Philippines** Both sexes, All ages, Percent of total DALYs 2016 rank 2021 rank

From five years ago, diabetes, anxiety disorders, and depressive disorders have risen up in the rankings

1 Neonatal disorders 1 COVID-19 2 Ischemic heart disease 2 Ischemic heart disease 3 Stroke 3 Stroke 4 Lower respiratory infect 4 Neonatal disorders 5 Tuberculosis 5 Other COVID Outcomes 6 Chronic kidney disease 6 Lower respiratory infect 7 Congenital defects 7 Diabetes 8 Diabetes 8 Chronic kidney disease 9 Interpersonal violence 9 Tuberculosis 10 Headache disorders 10 Interpersonal violence 11 Road injuries 11 Congenital defects 12 Low back pain 12 Headache disorders 13 COPD 13 Road injuries 14 Hypertensive heart disease 14 Low back pain 15 Asthma 15 Anxiety disorders 16 Age-related hearing loss 16 COPD 17 Diarrheal diseases 17 Depressive disorders 18 Anxiety disorders 18 Hypertensive heart disease 19 Cirrhosis liver 19 Age-related hearing loss 20 Depressive disorders 20 Asthma 21 Dietary iron deficiency 21 Cirrhosis liver 23 Blindness and vision loss 23 Dietary iron deficiency Source: Wong J. Phil Burden of Disease. January 2025 24 Diarrheal diseases 26 Blindness and vision loss www.philhealth.gov.ph PhilHealthOfficial

Communicable, maternal, neonatal, and nutritional diseases

Non-communicable diseases Injuries


Other COVID-19 pandemicrelated outcomes

### Change in life expectancy at birth: Both sexes from 1990 - 2021 by broad cause group

Click on bar for more details

Unlike other ASEAN countries, the life expectancy at birth in the Philippines did not change from 1990-2021

The lack of progress was mainly due to respiratory infections, TB, and other COVID outcomes



# Philippine Burden of Disease 2021 Challenges identified

- The 2021 Philippine Burden of Disease study reveals that just 35 diseases already account for 80% of Disability-Adjusted Life Years (DALYs)
- The top 10 diseases contribute to 47% of the total DALYs
- Ischemic heart disease and stroke remain the leading causes of disease burden
- The study highlights that, unlike other ASEAN countries, the life expectancy in the Philippines did not improve from 1990-2021
- Hypertension, malnutrition, air pollution, tobacco, and dietary risks are the top five risk factors
- Notable increases in the rankings of diabetes, anxiety disorders, and depressive disorders have occurred in the past 5 years

Source: Wong J. Phil Burden of Disease. January 2025





## PhilHealth Coverage for Diabetes-Related Treatments and Complications of Diabetes

Konsulta: Consultation, laboratory tests, medicines

Case Rates for Diabetes-related treatment (DKA)

IHD-Acute MI Benefit Package (PCI, fibrinolysis, EMS with interfacility transfer, cardiac rehab)

Inpatient Case Rates for Acute Stroke

Renal Replacement Therapy Benefit Package (HD, PD, KT)

Emergency Benefit Package (Hypertensive Emergency/Urgency)

Procedures: Debridement/Amputation for diabetic foot, Vitrectomy for diabetic retinopathy, etc.






### **Konsulta Coverage**

Consultation • Health Risk Screening and Assessment • Selected Laboratory and Diagnostic Test • Selected Drugs and medicines

| HEALTH SERVICES   | 15 DIAGNOSTICS  | 21 MEDICINES   |   |  |
|---|---|--|---|--|
| Health Risk Screening (TB, HIV, etc.)  Consultations with a Primary Care Provider  Wellness Consultations (Maternal & Child, Prenatal, etc.) Sick Consultations (TB, Malaria, etc.) Counselling (FP, health and lifestyle, smoking cessation, alcohol, mental health, etc.) | <ul> <li>CBC w/ platelet count</li> <li>Lipid profile (Total Cholesterol, HDL and LDL Cholesterol, Triglycerides)</li> <li>FBS</li> <li>OGTT</li> <li>HbA1c</li> <li>Creatinine</li> <li>Chest X-ray</li> <li>Sputum microscopy</li> <li>Electrocardiogram (ECG)</li> <li>Urinalysis</li> <li>Pap smear</li> <li>Fecalysis</li> <li>Fecal Occult Blood Test</li> <li>Mammogram</li> <li>Ultrasound (upper abdomen, breast, pelvic)</li> </ul> | <ul> <li>Amoxicillin</li> <li>Co-Amoxiclav</li> <li>Nitrofurantoin</li> <li>Cotrimoxazole</li> <li>Ciprofloxacin</li> <li>Clarithromycin</li> <li>Oral Rehydration Salts</li> <li>Prednisone</li> <li>Salbutamol</li> <li>Fluticasone + Salmeterol</li> <li>Paracetamol</li> </ul> | <ul> <li>Simvastatin</li> <li>Gliclazide</li> <li>Metformin</li> <li>Enalapril</li> <li>Metoprolol</li> <li>Amlodipine</li> <li>Hydrochlorothiazide</li> <li>Losartan</li> <li>Aspirin</li> <li>Chlorphenamine maleate</li> </ul> |  |
|   |   |  | * *   |  |







Coverage for hemodialysis: 156 Sessions/Year

Erythropoietin

Labs (Monitoring)

Dialyzer, Supplies Use of HD machine

Professional Fees





### Peritoneal Dialysis COVERAGE IN ADULTS

PD Catheter **Insertion and** Initiation



Continuous **Ambulatory Peritoneal Dialysis (CAPD)** 



**PD Related** Infection management

PHP 71,500

PHP 465,000/Year (3 bags/day)

PHP 585,500/Year (4 bags/day)

PHP25,000/Year (Peritonitis)

PHP29,200 (Exit Site & Peritonitis Prevention Care)

19



### PD COVERAGE IN PEDIATRIC ESRD PATIENTS

PD Catheter Insertion & Initiation



Continuous
Ambulatory
Peritoneal Dialysis
(CAPD)




PD Related Infection management

Automated Peritoneal Dialysis (APD)





### **Coverage for Kidney Transplantation**








## **Post-KT Service Coverage**





Laboratory/
Diagnostic Tests



Drugs/ Medicines



Donor monitoring



Specialist Services Fees





### **Utilization**

| ICD-10 | Description  | Claims Count |       | Amount Paid                   | Amount Paid (PHP)             |  |
|--------|--|--------------|-------|-------------------------------|-------------------------------|--|
|        |  | 2023         | 2024  | 2023                          | 2024                          |  |
| E10.1  | INSULIN-DEPENDENT DIABETES MELLITUS WITH ACIDIDOSIS/ KETOACIDOSIS WITHOUT MENTION OF COMA; DIABETIC ACIDIDOSIS WITHOUT MENTION OF COMA; DIABETIC KETOACIDOSIS WITHOUT MENTION OF COMA  | 1,022        | 1,095 | 15,979,162.15<br>(16 Million) | 22,014,388.31<br>(22 Million) |  |
| E11.1  | NON-INSULIN-DEPENDENT DIABETES MELLITUS WITH KETOACIDOSIS WITHOUT MENTION OF COMA;; NONOBESE DIABETES (MELLITUS) WITH KETOACIDOSIS WITHOUT MENTION OF COMA; OBESE DIABETES MELLITUS WITH KETOACIDOSIS WITHOUT MENTION OF COMA; ADULT-ONSET DIABETES MELLITUS | 1,707        | 1,886 | 26,210,069.24<br>(26 Million) | 37,834,509.27<br>(38 Million) |  |
| E13.1  | OTHER SPECIFIED DIABETES MELLITUS WITH ACIDIDOSIS/ KETOACIDOSIS WITHOUT MENTION OF COMA  | 94           | 69    | 1,444,257.2                   | 1,337,726.43                  |  |
| E14.1  | UNSPECIFIED DIABETES MELLITUS; DIABETES NOS<br>WITH ACIDIDOSIS/ KETOACIDOSIS WITHOUT MENTION<br>OF COMA  | 913          | 972   | 14,221,125.57<br>(14 Million) | 19,427,324.49<br>(19 Million) |  |

Source: PhilHealth Claims Database, as of 31 March 2025





### **Utilization**

| Benefit Package                   | No. of Claims |           | Amount Paid (PHP) |                |  |
|-----------------------------------|---------------|-----------|-------------------|----------------|--|
|                                   | 2023          | 2024      | 2023              | 2024           |  |
| Hypertensive<br>Emergency/Urgency | 141,436       | 231,494   | 1,158,655,165     | 2,316,433,542  |  |
| Stroke Infarction                 | 128,054       | 99,418    | 3,565,152,999     | 4,949,579,602  |  |
| Hemodialysis Procedure            | 3,627,350     | 5,190,286 | 17,435,331,944    | 28,162,018,203 |  |

Source: PhilHealth Stats & Charts, 2023-2024





# Future Direction Diabetes and Other NCDs

- 1. Prioritizing prevention and primary healthcare Expanding Konsulta to Comprehensive Outpatient Benefit Package
- Adopting a broader framework that integrates health needs, disease burden, equity, stakeholder values, and cost-effectiveness data – PhilHealth Benefits Development Planning Protocol (Corporate Order No. 2024-0003)
- 3. Using provider payment mechanisms and strategic purchasing to influence healthcare provider practice and health-seeking behavior
- 4. Robust stakeholder engagement and communications



